Table 2.
Base case results
| 9-valent vaccine | Quadrivalent vaccine | Bivalent vaccine | |
| Discounted net costs | $611 | $380 | $278 |
| Discounted DALYs prevented | 0.0265 | 0.0199 | 0.0199 |
| ICER of 9-valent vaccine vs other vaccines | NA | $35 000 | $50 455 |
| ICER vs not being vaccinated | $23 012 | $19 061 | $13 944 |
| Price threshold of 9-valent vaccine to be cost-effective vs other vaccines* | NA | $550 | $450 |
| Price threshold of 9-valent vaccine to be highly cost-effective vs other vaccines† | NA | $435 | $335 |
| Price threshold of 9-valent vaccine to be as cost-effective as other vaccines‡ | NA | $505 | $370 |
| Price threshold to be cost-effective vs not being vaccinated | $680 | NA | NA |
| Price threshold to be highly cost-effective vs not being vaccinated | $220 | NA | NA |
*For example, the 9-valent vaccine should be priced at $550 for the full doses to be cost-effective when compared with the quadrivalent vaccine.
†For example, the 9-valent vaccine should be priced at $435 for the full doses to be highly cost-effective when compared with the quadrivalent vaccine.
‡At this price, the 9-valent vaccine is as cost-effective as the quadrivalent vaccine when each of them was compared with not receiving vaccination if the price of the 9-valent vaccine is $505 for the full doses. This is equivalent to saying that the cost-effectiveness of the 9-valent vaccine vs the quadrivalent vaccine is the same as the cost-effectiveness of the quadrivalent vaccine vs not receiving vaccination. The interpretation of the comparison vs the bivalent vaccine is the same.
DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio measured as incremental costs per DALY prevented; NA, not applicable.